Info

SR One invests globally in emerging biotech companies that are focused on drug discovery, development or delivery and have the potential to make products that can have a dramatic benefit to patients. We are interested in companies with products that are in preclinical development through clinical proof-of-concept. Overall, we look for investments that can provide attractive financial returns and significant strategic value. We have a Team of seven investment professionals that serve as the Fund's managers and Investment Committee. We understand the challenges facing emerging companies. Together, we bring practical industry expertise, an operational orientation and long-term perspective, from the beginning of the investment process through all aspects of value creation. Our investment record and focus on returns aligns us with financial investors and our industry perspective positions us to work effectively with company management teams.